Modality
ASO
MOA
KRASG12Ci
Target
Menin
Pathway
Checkpoint
DLBCLMCC
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
Jun 2019
→ Oct 2026
Phase 2Current
NCT06468551
2,439 pts·MCC
2019-06→2026-10·Not yet recruiting
2,439 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-026mo awayPh3 Readout· MCC
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-10-02 · 6mo away
MCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06468551 | Phase 2/3 | MCC | Not yet recr... | 2439 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| Lisolucimab | Novartis | Approved | CD20 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| ALN-6288 | Alnylam | Approved | LAG-3 |